Product Image

Contributor Information

  • Name Anne Lykkesfeldt
  • Institute Danish Cancer Society

Tool Details

  • Tool name: T47D/S2 Cell Line
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: T47D
  • Organism: Human
  • Tissue: Breast
  • Cancer type: Breast carcinoma
  • Disease: Cancer
  • Model: Tumour line
  • Conditional: Yes
  • Description: The T47D/S2 Cell line is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2 lines. Antiestrogen resistance is a major problem in breast cancer treatment. Therefore, the search for new therapeutic targets and biomarkers for antiestrogen resistance is crucial. This cell line allows the study of the mechanisms involved in tamoxifen resistant breast cancer cell growth. This is the control cell line for the tamoxifen resistant T47D/TR-1 and T47D/TR-2. T47DS2 cells express ER alpha and progesterone receptor. Passage 151 (AL3707, AL3708)
  • Research area: Cancer ; Drug Discovery & Development
  • Production details: T47D/S2 cells have been established by reduction of the serum concentration to 2% fetal calf serum, in order to enable growth inhibition with tamoxifen.
  • Cellosaurus ID: CVCL_1D45

  • For Research Use Only

Target Details

  • Target: Oestrogen receptor

Application Details

  • Application notes: T47DS2 cells express ER alpha and progesterone receptor.

Handling

  • Format: Frozen
  • Passage number: Passage 151 (AL3707, AL3708)
  • Growth medium: Phenol red free RPMI 1640 + 2% FCS + glutamax + 8Äžg Insulin/ml
  • Storage conditions: Liquid Nitrogen
  • Shipping conditions: Dry ice
  • Mycoplasma free: Yes
  • Biosafety level: 1

Documentation

  • Available on request

References

  •   Larsen et al. 2015. PLoS One. 10(2):e0118346. PMID: 25706943.
  •   Larsen et al. 2015. BMC Cancer. 15:239. PMID: 25885472.
  •   Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
  •   SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.
  •   Thrane et al. 2014. Oncogene. :. PMID: 25362855.
  •   A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.